Thermo Fisher Scientific Opens New GMP-certified Ultra-cold Facility in the EU to Accelerate Advanced Therapies Development
3.6.2024 09:00:00 EEST | Business Wire | Press release
Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced therapies. The new current good manufacturing practice (cGMP) facility in Bleiswijk, Netherlands provides pharma and biopharma customers tailored, end-to-end support throughout the clinical supply chain for high-value therapies, including cell and gene therapies, biologics, antibodies and vaccines.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240602205471/en/
Thermo Fisher Scientific announces the opening of a new site in the Netherlands specializing in ambient to cryogenic storage, clinical and commercial packaging, labeling, and distribution, and clinical QP release services (Photo: Business Wire)
To meet increasing demand from cell and gene therapy clinical trials in Europe, this state-of-the-art facility builds on the company’s market leadership and global CDMO capabilities in bioservices and specialty logistics services, including biorepository solutions and critical material storage. The facility enables customers to meet clinical trial requirements regardless of scale or phase by leveraging its highly skilled and talented local workforce to partner with new and emerging biotech and established pharmaceutical companies.
“The opening of this cutting-edge facility supporting the development of cell and gene therapies and other biologics, coupled with our proven track record in managing valuable materials, places us in an unmatched position to help our global clients develop innovative therapies,” said Molly Flick, vice president and general manager, bioservices & specialty logistics, Thermo Fisher Scientific.
The site, 30 minutes outside of Amsterdam, offers clinical and commercial packaging services for cell and gene therapy products from development to commercialization, as well as end to end biorepository storage solutions and associated supply chain services. Capabilities include 5,000-square-meters (54,000 square feet) of ambient to cryogenic storage, ancillaries, and cold chain packaging, labeling, distribution as well as clinical QP release services.
In support of Thermo Fisher’s commitment to sustainability and its global goal of achieving net-zero emissions by 2050, the Bleiswijk site uses 15% solar power and operates completely gas-free, provides sustainable heating and cooling with eco-friendly electric heat pumps, and uses ultramodern heat recovery technology.
Thermo Fisher is dedicated to delivering end-to-end solutions to advance inclusive, impactful clinical research. In addition to the new facility in the EU, Thermo Fisher also recently expanded biologics manufacturing capacity in St. Louis, opened a new cell therapy manufacturing facility in San Francisco, and launched an Innovation Lab in Pennsylvania. To learn more about the company’s capabilities, please visit thermofisher.com/patheon.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240602205471/en/
Contact information
Media:
Abbie Martin
Phone: (774) 847-4508
Email: abbie.martin@thermofisher.com
Emily Landers
Phone: (617) 275-6527
Email: elanders@greenoughagency.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetApp Enhances Support for AI Workloads at Massive Scale23.6.2026 17:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced the release of StorageGRID 12.1, designed to help customers scale AI and other modern workloads with a federated global namespace. The new capabilities improve how data is accessed, processed, and managed across distributed environments to support AI data pipelines, data lakes, and modern object-based applications. Organizations are contending with rapid growth in unstructured data to serve AI workloads while also managing that data across increasingly distributed hybrid environments. In its Object Storage Solutions Landscape, Q1 2026 report, Forrester notes that the rise of generative AI has pushed object storage further into an AI‑optimized data platform beyond its historical uses supporting enterprise data strategies with scalable, durable storage for unstructured data, media, and backups. The updates to NetApp StorageGRID enable organizations to leverage their object data for these emerging uses wi
Otonal Launches Localization Service to Adapt English Podcasts and Audio Ads for the Japanese Market23.6.2026 17:00:00 EEST | Press release
Otonal Inc., a Tokyo-based digital audio advertising and podcast technology company, has officially launched a specialized audio localization service designed to help global brands and media companies adapt their English-language podcasts and audio advertisements for the Japanese market. Audio Ad Localization https://otonal.co.jp/en/audioad-localization/ Podcast Localization https://otonal.co.jp/en/podcast-localization/ While many translation vendors focus on text-based, one-size-fits-all translation, Otonal’s service addresses the distinct challenges of audio-first localization. The service goes beyond standard translation by rebuilding scripts for spoken Japanese, ensuring precise 15- and 30-second ad timings, adapting the content to local cultural context, and casting native Japanese voice talent suited to the content and delivery environment to maintain brand authority and tone. Japan ranks among the world's leading economies and is one of Asia’s largest advertising markets, making
GigaDevice and Qt Group Announce Global Partnership to Advance the Embedded GUI Ecosystem23.6.2026 17:00:00 EEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, has officially entered a strategic partnership with Qt Group, a global leader in software design, development, and quality assurance solutions. Leveraging the GD32H7 high-performance MCU series, the two companies will collaborate to optimize and enhance embedded GUI solutions, enabling developers to create more intuitive, visually rich, and responsive user experiences. This collaboration further expands GigaDevice’s ecosystem strategy in advanced human-machine interface (HMI) and establishes a solid foundation for future innovation across smart industry solutions, energy storage systems, smart home devices, and consumer electronics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623351273/en/ GigaDevice and Qt Group Announce Global Partnership to Advance the Embedded GUI Ecosystem As IoT,
Andersen Global Adds Andersen in Indonesia23.6.2026 16:30:00 EEST | Press release
Andersen Global strengthens its footprint in Southeast Asia as VDB Loi in Indonesia rebrands to Andersen in Indonesia, becoming the newest member firm to join the organization. Andersen in Indonesia provides tax and legal advisory services to multinational companies and foreign investors operating in the Indonesian market. The firm combines decades of market experience with a practical approach focused on delivering clear, tailored guidance across complex regulatory and cross-border matters. “Adopting the Andersen brand reflects our commitment to providing clients with high-quality, practical tax and legal advice supported by broader international collaboration,” said Tommy Hendharto Oetomo, managing partner of Andersen in Indonesia. “Clients operating in Indonesia require increasingly coordinated cross-border support. Becoming a member firm strengthens our ability to deliver that service with consistency and clarity.” “Indonesia remains an important market for organizations investing
Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 16:30:00 EEST | Press release
Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Research and Development and Chief Medical Officer, Healthcare business of Merck. “By leveraging Saturnus' expertise and cutting-edge approach, we can build upon our armed antibodies capabilities and explore novel directions to rapidly bring new, targeted treatments to patients.” “The launch of Saturnus through a foundati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom